Squalamine prevents aggregation of alpha-synuclein (αS) and competes with it for binding to phospholipid membranes (KD of squalamine 67 nM versus 380 nM for synuclein), which can be used to treat Parkinson’s disease [148]. The gene discussed is SNCA; the disease is Parkinson disease.